Explain 'skeletal editing' in synthetic chemistry. How can atom-level editing of molecules transform drug discovery? Discuss its relevance for India's ambition to move from generic to innovative pharmaceuticals.

In September 2026, University of Chicago chemists reported in Science a reaction that replaces a carbon atom in a ring with a nitrogen atom under mild conditions [1]. This is a landmark in skeletal editing. Such atom-level precision can speed up drug discovery and help India's pharma sector move from generics to new medicines.

What is skeletal editing?

• Conventional synthesis changes the groups attached around a molecule's core. Skeletal editing inserts, deletes or swaps single atoms within the core ring itself.
• The UChicago method used the triplet state of a nitrene, which chemists had earlier seen as unproductive. It opens the ring, rearranges the atoms and closes it again, leaving N where C stood [1].

Ring with C → [triplet nitrene] → ring opens → atoms rearrange → ring closes → Ring with N

Fig: Mild C→N atom swap

Transforming drug discovery

• Property tuning: A single C→N swap changes solubility and binding to biological targets, two factors that decide whether a drug candidate succeeds [1].
• Late-stage editing: Earlier routes needed powerful oxidants that damaged other parts of the molecule. Mild conditions let chemists edit complex molecules directly, as shown on an anti-cancer Vinca alkaloid [1].
• Wider chemical space: The method gave a 73% yield on an indole that earlier methods could not convert [1]. Chemists can make variants of existing scaffolds instead of building each molecule from scratch.
• Greener chemistry: Fewer harsh reagents means potentially less hazardous waste.
• Caveat: This is a discovery tool, not a drug. Every edited molecule still has to pass preclinical and clinical trials.

Relevance for India

• Policy intent: The National Policy on R&D and Innovation in Pharma-MedTech (2023) aims to move the sector towards innovation-led growth [2].
• Funding: The PRIP scheme (₹5,000 crore) [3] expects to support about 300 projects with around ₹11,000 crore of total R&D investment [4]. Its seven NIPER Centres of Excellence include work on flow chemistry and continuous manufacturing [5], which makes them natural homes for synthetic-methods research.
• Gap: Most PRIP money goes to industry and startup projects [3]. Curiosity-driven method chemistry, where breakthroughs like UChicago's begin, risks getting less support.
• IPR: Section 3(d) of the Patents Act, 1970 limits patents on new forms of known substances [6]. Atom-swapped analogues must therefore show a real therapeutic gain, which discourages evergreening.

Skeletal editing lets chemists edit molecules one atom at a time, which shortens the search for a drug lead. India can turn its generic-manufacturing strength into genuine drug innovation. The steps are to fund synthetic-methods labs at the NIPER Centres of Excellence and to link academia with industry under the 2023 policy [2]. This would advance SDG 3 and Atmanirbhar Bharat.